TIMOTHY JOHN MEYER
Pilots at Spg Hl Dr, Saint Paul, MN

2013004, Feb 21, 2013

Jun 28, 2012

13/536526

Craig M. Stolen - New Brighton MN, US
Harlan Bos - Stillwater MN, US
Timothy E. Meyer - North Oaks MN, US
Arjun Sharma - St. Paul MN, US

CARDIAC PACEMAKERS, INC. - St. Paul MN

A61B 5/0452, A61N 1/365

600515, 607 14

Embodiments of the invention are related to systems and methods for setting parameters of implantable medical devices, amongst other things. In an embodiment, the invention includes a method for programming an implantable medical device including sensing concentrations of a predictive marker such as ET-1 in a patient, selecting programming parameter values based on the sensed concentrations of the predictive marker, and implementing the selected programming parameter values. In an embodiment the invention includes a method for detecting arrhythmia in a patient including sensing concentrations of the predictive marker in a patient, selecting a level of stringency to be used in an arrhythmia detection module based on the sensed concentrations of the predictive marker, sensing electrical signals in the patient, and evaluating the sensed electrical signals for indicia of an arrhythmia using the arrhythmia detection module. Other embodiments are also included herein.

8602996, Dec 10, 2013

May 31, 2011

13/118932

Pramodsingh Hirasingh Thakur - White Bear Lake MN, US
Abhilash Patangay - Inver Grove Heights MN, US
Craig Stolen - New Brighton MN, US
Timothy Meyer - North Oaks MN, US

Cardiac Pacemakers, Inc. - St. Paul MN

A61B 5/02

600483, 600509

Devices and methods for improving the sensitivity and specificity of heart failure (HF) detection are described. The devices and methods can detect a HF status such as using physiological sensor data and external biomarker assays. An apparatus can comprise ambulatory physiological sensors that can provide a first HF status indicator and a second HF status indicator to a user. An external biomarker sensor can provide an amount of a biomarker present, such as an assay for B-type natriuretic peptide (BNP), which provides information about HF status. A processor circuit can switch from a first HF detection mode to a second detection mode such as in response to the information from the biomarker sensor. The first detection mode can detect HF status using the first HF status indicator, and the second detection mode can detect HF status using the second HF status indicator. The second detection mode can have a higher specificity than the first detection mode.

2013019, Aug 1, 2013

Jan 31, 2013

13/756135

Craig M. Stolen - New Brighton MN, US
Timothy E. Meyer - North Oaks MN, US
Milan Seth - Minneapolis MN, US
Francis G. Spinale - Blythewood SC, US
Nicholas David Wold - Arden Hills MN, US

MEDICAL UNIVERSITY OF SOUTH CAROLINA - Charleston SC
CARDIAC PACMAKERS, INC. - St. Paul MN

A61B 5/145, A61N 1/365, A61B 5/00

506 9, 435 792, 436501, 435 612, 600309, 204450

Embodiments of the disclosure are related to systems and methods for utilizing biomarker panel data and related medical devices and methods, amongst other things. An embodiment can include a method of screening patients. The method can include quantifying levels of one or more of a panel of biomarkers in a biological sample of a patient. The method can further include analyzing the quantified levels. In some embodiments, the panel of biomarkers includes at least two selected from the group consisting of CRP, SGP-130, sIL-2R, sTNFR-II, IFNg, BNP, sST2, MMP-2, MMP-9, TIMP-1, TIMP-2, TIMP-4. In an embodiment, the disclosure can include a method of diagnosing a patient. The method can include quantifying levels of one or more of a panel of biomarkers in a biological sample of a patient. The method can further include diagnosing the patient based at least in part on the quantified levels. In some embodiments, the panel of biomarkers includes at least two selected from the group consisting of CRP, SGP-130, sIL-2R, sTNFR-II, IFNg, BNP, sST2, MMP-2, MMP-9, TIMP-1, TIMP-2, TIMP-4. Other embodiments are also included herein.

8362903, Jan 29, 2013

Apr 30, 2009

12/432939

Par Lindh - Maple Grove MN, US
Donovan Benton Fellows - Woodbury MN, US
Timothy E. Meyer - North Oaks MN, US
Paul Jones - St. Paul MN, US
Kenneth I. Tobacman - Cedar MN, US

Cardiac Pacemakers, Inc. - St. Paul MN

G08B 23/00

3405731, 3405391, 34053911, 34053913, 340665, 340666, 340667

A system and method for providing enhanced weight alert notification during automated patient management is presented. A plurality of weight measurements in an automated patient environment from a weight monitoring device for a patient during an observation period is remotely obtained. A raw baseline weight for the patient is determined based on a function of the weight measurements. Irregularities in the weight measurements are identified. The raw baseline weight is processed into a baseline weight by application of a correction coefficient to the irregularities. Weight remotely measured in the automated patient environment for the patient on a substantially regular basis is obtained. Changes in the weight are identified by periodic comparison to the baseline weight. An alert notification is generated in response to the change in weight.

2014003, Jan 30, 2014

Sep 30, 2013

14/041682

Abhilash Patangay - Inver Grove Heights MN, US
Craig Stolen - New Brighton MN, US
Timothy Meyer - North Oaks MN, US

Cardiac Pacemakers, Inc. - St. Paul MN

A61B 5/0205

600301

Devices and methods for improving the sensitivity and specificity of heart failure (HF) detection are described. The devices and methods can detect a HF status such as using physiological sensor data and external biomarker assays. An apparatus can comprise ambulatory physiological sensors that can provide a first HF status indicator and a second HF status indicator to a user. An external biomarker sensor can provide an amount of a biomarker present, such as an assay for B-type natriuretic peptide (BNP), which provides information about HF status. A processor circuit can switch from a first HF detection mode to a second detection mode such as in response to the information from the biomarker sensor. The first detection mode can detect HF status using the first HF status indicator, and the second detection mode can detect HF status using the second HF status indicator. The second detection mode can have a higher specificity than the first detection mode.

2013023, Sep 12, 2013

Jan 31, 2013

13/756129

Craig M. Stolen - New Brighton MN, US
Timothy E. Meyer - North Oaks MN, US
Milan Seth - Minneapolis MN, US
Francis G. Spinale - Blythewood SC, US
Nicholas David Wold - Arden Hills MN, US

MEDICAL UNIVERSITY OF SOUTH CAROLINA - CHARLESTON SC
CARDIAC PACEMAKERS, INC. - ST. PAUL MN

G01N 33/68

506 9, 435 792

Embodiments of the disclosure are related to systems and methods for utilizing biomarker panel data with respect to medical devices and methods, amongst other things. In an embodiment, the disclosure can include a method of predicting the likelihood of response to CRT therapy. The method can include quantifying levels of one or more biomarkers in a biological sample of a patient, analyzing the quantified levels to determine response to CRT therapy, wherein a panel of biomarkers includes at least two selected from the group consisting of CRP, SGP-130, sIL-2R, sTNFR-II, IFNg, BNP, sST2, MMP-2, MMP-9, TIMP-1, TIMP-2, TIMP-4. Other embodiments are also included herein.

2009012, May 14, 2009

Nov 12, 2008

12/269558

Allan C. Shuros - St. Paul MN, US
Craig Stolen - New Brighton MN, US
Timothy Meyer - North Oaks MN, US
Stephen Ruble - Lino Lakes MN, US

Cardiac Pacemakers, Inc - st paul MN

A61N 1/365

607 17

This document discusses, among other things, a system and method for calculating a neural stimulation energy at an external patient management (EPM) system using received information about a chemical characteristic indicative of a physiological state of a subject.